Precision Targeting of Hepatic Stellate Cells: Nanotherapeutic Strategies for Liver Fibrosis Regression

Liver fibrosis (LF), a major global health burden causing over two million deaths annually, arises from chronic injury leading to hepatic stellate cell (HSC) activation and pathological extracellular matrix (ECM) deposition. Current therapies are limited by nonspecific biodistribution and inadequate drug delivery to HSCs. Nanosystems engineered for active HSC targeting offer a promising approach to overcome fibrotic barriers-including capillarized sinusoids and dense ECM-through strategies such as receptor-specific ligand modification, RNA-based gene silencing, and multifunctional combinatorial therapies. These platforms enable precise modulation of HSC activation and ECM remodeling, promoting fibrosis regression while sparing healthy tissue. Despite promising preclinical outcomes, key challenges remain in biosafety, scalable fabrication, and clinical validation. Advancements in HSC-specific nanotherapeutics hold transformative potential for reversing liver fibrosis and restoring hepatic function. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.